Study Objective

This study compares the metabolic-related molecular profiles observed in non-small cell lung cancer (NSCLC) patients after treatment with immune checkpoint inhibitors (ICIs). The aim is to elucidate the impact of metabolic pathways on treatment response, with the goal of identifying novel biomarkers to overcome resistance to existing ICI therapies.

Study Design

A prospective observational study involving the collection of patient samples for analysis of metabolic-related gene and protein expression. The primary endpoint is the correlation between ICI response (responder vs. non-responder) and metabolic profiles. The anticipated completion date is not specified, but the study commenced on July 24, 2024, and is currently recruiting.

Differentiation from Current Treatment Landscape

While ICIs are currently a first-line treatment option for NSCLC, approximately 30% to 40% of patients develop resistance. This study differentiates itself by focusing on metabolic pathways, aiming to understand how the energy utilization of immune cells affects treatment outcomes. The identification of novel metabolic biomarkers could be a key asset in designing personalized treatment strategies.

Clinical and Industrial Impact

If the biomarker is validated, pharmaceutical companies can rapidly initiate clinical trials combining ICIs with metabolic modulators. This is expected to yield higher response rates compared to ICI monotherapy, contributing to increased market share and the development of new therapeutic pipelines. Furthermore, additional revenue streams may be generated through the development of diagnostic kits.